| SHPHF Stock | | | USD 0.19 0.02 11.76% |
The math operators module provides an execution environment for Price Series Summation operator and related indicators on Sihuan Pharmaceutical and Fagron NV. The focus on relative price relationships between Sihuan Pharmaceutical and Fagron NV helps organize trend, volatility, and risk context for Sihuan Pharmaceutical and Fagron NV.
Most technical analysis of Sihuan Pharmaceutical help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Sihuan from various momentum indicators to cycle indicators. When you analyze Sihuan charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the Peoples Republic of China. The company was founded in 2001 and is based in Wanchai, Hong Kong. Sihuan Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 3896 people. As a mid-cap equity, Sihuan Pharmaceutical is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/E of 8.75, P/B of 0.81, profit margin of -5.43%. Sihuan Pharmaceutical has market cap of 1.2 B, P/E of 8.75, ROE of -4.87%.
Methodology
Unless otherwise specified, financial data for Sihuan Pharmaceutical Holdings is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Sihuan (USA Stocks:SHPHF) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR. Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Sihuan Pharmaceutical Holdings may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking Sihuan Pharmaceutical inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Sihuan Pharmaceutical financial ratios help frame valuation context across profits, cash flow, and enterprise value. They help compare Sihuan across valuation measures and peers.